Gujarat Inject Kerala Ltd (524238)
சுருக்கம்
நிகழ்வுகள்
- சமீபத்திய முடிவுகள்
- Q2 FY27, தாக்கல் செய்யப்பட்டது 5 நவ. 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 29 அக். 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
Gujarat Inject Kerala Ltd reported Q2 FY27 results on 5 Nov 2026: revenue ₹5.8 Cr (+268.3% year on year, -53.3% on the previous quarter), and net profit ₹0.7 Cr (+936.1% year on year); the operating margin was 17.8%.
| Q2 FY27 (₹ கோடி) | மதிப்பு | YoY Q2 FY26-உடன் | QoQ |
|---|---|---|---|
| வருவாய் | ₹5.8 | +268.3% | -53.3% |
| செயல்பாட்டு லாபம் | ₹1.0 | — | -38.6% |
| நிகர லாபம் | ₹0.7 | +936.1% | -42.1% |
| EPS (₹) | 0.05 | — | -41.9% |
| செயல்பாட்டு லாப வரம்பு | 17.8% | — | — |
EPS restated for the ₹10 to ₹1 split of Jul 2026: Q1 FY27 ₹0.86 to ₹0.09.
- லாபம் அதன் சொந்தப் போக்கை விட +418% மேலே
- செயல்பாட்டு லாப வரம்பு 1591 bps YoY அதிகரித்தது
- லாபம் இருந்தும் H1 FY27 செயல்பாட்டுப் பணப்புழக்கம் எதிர்மறையாக இருந்தது
லாபத்தின் தரம்: வரிக்கு முந்தைய ₹1.0 கோடி லாபத்தில், ₹1.0 கோடி (100%) முக்கிய வணிகத்திலிருந்து வந்தது; மீதம் பிற வருமானம் மற்றும் ஒருமுறை வரவுகளிலிருந்து வந்தது.
அதன் சொந்தப் போக்குக்கு எதிராக: நிகர லாபம் ₹0.7 கோடியாக இருந்தது; இது, அதன் சமீபத்திய வளர்ச்சி சுட்டிக்காட்டிய ₹0.1 கோடியுடன் ஒப்பிடும்போது +418.1% ஆகும் (above trend). இது ஒரு புள்ளியியல் அடிப்படை மட்டுமே; ஆய்வாளர் மதிப்பீடு அல்ல.
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Gujarat Inject Kerala reported Q2 FY27 standalone revenue from operations of Rs 5.82 crore, up 269% YoY from Rs 1.58 crore in Q2 FY26, but down 53% QoQ from Rs 12.45 crore. Net profit for the quarter stood at Rs 0.73 crore compared to Rs 0.07 crore in Q2 FY26. Notably, statutory auditors issued a qualified opinion regarding unprovided trade receivables of Rs 5.74 crore overdue for over a year (which represents nearly 48% of the company's Rs 12 crore net worth). The quarter also marked the commercialization of its Solar Power Generation segment, which contributed Rs 1.00 crore in revenue and Rs 0.98 crore in EBITDA.
- Q2 revenue reached Rs 581.98 lakh compared to Rs 157.63 lakh in Q2 FY26 and Rs 1,245.45 lakh in Q1 FY27
- Net profit for the quarter was Rs 72.53 lakh versus Rs 6.75 lakh in Q2 FY26
- Auditor raised qualification on overdue trade receivables of Rs 574.16 lakh (>1 year) without ECL provisioning
- Auditor flagged unconfirmed non-current loans and advances of Rs 431.42 lakh
- New Solar Power Generation segment commenced operations, delivering revenue of Rs 99.81 lakh and EBITDA of Rs 97.89 lakh
Gujarat Inject Kerala Limited has signed two 5-year lease agreements for industrial premises at Metro Industrial Park, Sanand, Ahmedabad. The leased properties (Plot/Shed Nos. 30 and 31) will support factory operations and R&D focused on emerging technology in thermal and renewable energy. Both leases feature a 2-year lock-in period and an annual rent escalation of 5%. This signals a strategic diversification beyond its traditional pharmaceutical business, which generated Rs 46 Cr in TTM revenue.
- Executed lease agreements for two industrial sheds (Nos. 30 and 31) in Sanand, Ahmedabad
- Lease tenure fixed at 5 years with a 2-year lock-in period
- Annual lease rent escalation set at 5%
- Facilities dedicated to R&D and factory operations in thermal and renewable energy
Gujarat Inject Kerala Ltd has executed two separate 5-year lease agreements for Plot/Shed Nos. 30 and 31 at Metro Industrial Park in Moraiya, Sanand, Ahmedabad. The premises will be utilized for factory and business operations, specifically including R&D in thermal and renewable energy alongside ancillary activities. Each agreement carries an annual escalation of 5%, a 2-year lock-in period for the lessee, and an interest-free refundable security deposit of ₹1,55,000. This operational setup marks an expansion beyond its traditional pharma segment into energy-related R&D.
- Lease tenure set at 5 years with a 2-year lock-in period for the lessee
- Security deposit of ₹1,55,000 per agreement (interest-free and refundable)
- Annual lease rent escalation fixed at 5%
- Covers two separate premises (Plot/Shed Nos. 30 and 31) at Metro Industrial Park, Moraiya, Sanand
- Intended for factory operations and R&D in thermal and renewable energy
Gujarat Inject Kerala Ltd has approved raising funds via the preferential issuance of up to 3,00,00,000 equity warrants of face value ₹1 each, aggregating to ₹3,00,00,000. The warrants will be allotted to 11 non-promoter/public investors, with JV Investment holding the largest portion at 1,90,00,000 warrants. The board has also proposed to increase authorized share capital from ₹15 Cr to ₹17.63 Cr. The issue price will be set per SEBI ICDR guidelines, subject to shareholder and regulatory approvals.
- Proposed issuance of 3,00,00,000 equity warrants of face value ₹1 each aggregating up to ₹3,00,00,000
- Increase in authorized share capital from ₹15,00,00,000 to ₹17,63,48,000
- Preferential allotment to 11 non-promoter/public investors, led by JV Investment (1,90,00,000 warrants)
- Warrants convertible into equity shares within 18 months from the allotment date
- Fundraise face value represents ~10% of the current market capitalization of ~₹30 Cr
Gujarat Inject Kerala Ltd has rescheduled its Board of Directors meeting from October 26, 2026, to October 29, 2026. The agenda remains to consider and approve a proposal for issuing equity shares and/or equity warrants via a preferential allotment. The company currently has a market capitalization of Rs 30 Cr and TTM revenue of Rs 46 Cr. Pricing, dilution size, and allotment value have not yet been disclosed and will depend on board approval.
- Board meeting rescheduled from October 26, 2026, to October 29, 2026
- Meeting agenda includes considering equity shares and/or equity warrants via preferential allotment
- Company currently operates with a market cap of approximately Rs 30 Cr and zero debt
- Proposal remains subject to regulatory and statutory approvals
Gujarat Inject Kerala Ltd has scheduled a Board of Directors meeting on October 26, 2026, to consider a preferential issue of equity shares and equity warrants. The company currently has a market capitalization of Rs 30 Cr and zero debt on its balance sheet. Specific terms, including the quantum of funds to be raised, issue price, and proposed allottees, have not yet been disclosed and will depend on board approval. Note that the filing body contains clerical drafting references to another corporate name, which requires clarification.
- Board meeting scheduled for Monday, 26th October 2026
- Agenda includes issuance of Equity Shares (including Equity Warrants) via preferential allotment
- Fundraise subject to SEBI ICDR Regulations, 2018 and Companies Act approvals
- Document text mistakenly references 'Ecofinity Atomix Limited' in the body text
Gujarat Inject Kerala Ltd has secured a purchase order valued at approximately ₹6.25 crore from Deon Energy Limited. The contract entails the supply and arrangement of 8,065 solar modules of 620 Wp. The order represents roughly 13.6% of the company's TTM revenue of ₹46 crore and is slated for completion within October 2026. The contract does not involve related party transactions.
- Received purchase order valued at around ₹6.25 crore from Deon Energy Limited
- Scope covers supply and arrangement of 8,065 solar modules of 620 Wp
- Scheduled for completion by October 2026
- Order value represents ~13.6% of TTM revenue (₹46 crore)
Gujarat Inject Kerala Ltd announced a major business pivot toward renewable energy, securing a ₹4.86 crore order from Zentaraa Infra Projects for 3,600 Solar PV modules to be executed in October 2026. The company capitalized ₹2,076.45 lacs (₹20.76 crore) as Capital Work in Progress (CWIP) toward a solar power project following an agreement with Soleos Energy. For FY26, total revenue reached ₹3,632.04 lacs (₹36.32 crore) and PAT rose to ₹181.41 lacs (₹1.81 crore), driven largely by its asset-light trading operations. No operational revenue was recorded from the solar generation project in FY26 as consideration discharge remains pending.
- Secured domestic purchase order worth ₹4.86 crore (exclusive of GST) for 3,600 Solar PV Modules from Zentaraa Infra Projects.
- Recognized ₹2,076.45 lacs as Capital Work in Progress (CWIP) toward Solar Power Generation Project.
- FY26 total revenue almost doubled to ₹3,632.04 lacs compared to ₹1,904.58 lacs in FY25.
- FY26 PAT grew to ₹181.41 lacs from ₹101.72 lacs in the previous fiscal year.
- Order execution scheduled for October 2026, while solar project capitalization was flagged as a Key Audit Matter by auditors.
Gujarat Inject Kerala Ltd has secured a domestic purchase order valued at approximately ₹4.86 crore (exclusive of GST) from Zentaraa Infra Projects Private Limited. The order entails supplying 3,600 solar PV modules across required sites and is scheduled for execution within October 2026. The contract represents approximately 10.6% of the company's TTM revenue of ₹46 crore and around 16.2% of its ₹30 crore market cap. Notably, the company, traditionally classified under pharmaceuticals, continues to register revenue from solar supply contracts.
- Order value is approximately ₹4.86 crore (exclusive of GST)
- Contract involves the supply of 3,600 units of Solar PV Modules
- Scheduled for rapid execution within October 2026
- Customer is domestic entity Zentaraa Infra Projects Private Limited, with no promoter or related-party interest
Gujarat Inject (Kerala) Limited has entered into a strategic business partnership with UK-based Storenergy Limited to explore Renewable Energy Storage Technology (REST) opportunities in India. The agreement establishes a framework to identify, evaluate, and develop potential storage projects. Commercial terms and financial arrangements for individual projects remain unfinalized and will be decided at a later stage. The company reported a net profit of Rs 1.25 cr on revenue of Rs 12.45 cr in the June 2026 quarter.
- Entered strategic partnership with UK-based Storenergy Limited for Renewable Energy Storage Technology (REST) in India.
- Commercial terms for individual projects are not yet finalized and will be agreed upon at a later stage.
- Transaction confirmed to be a non-related party transaction.
- Company posted revenue of Rs 12.45 cr and PAT of Rs 1.25 cr in the Jun 2026 quarter.
Gujarat Inject Kerala Ltd has appointed Mr. Radadiya HardikKumar AnilBhai as the Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) effective August 10, 2026. The appointee brings 7 years of experience in accounting, taxation, and financial reporting. The Board of Directors approved this appointment in a meeting held on the same day, which lasted 45 minutes. This change also updates the authorized personnel for determining materiality of events under SEBI LODR regulations.
- Appointment of Mr. Radadiya HardikKumar AnilBhai as CFO effective August 10, 2026
- New CFO possesses 7 years of professional experience in the accounting and taxation field
- Board meeting for the appointment concluded within 45 minutes (04:00 P.M. to 04:45 P.M.)
- Appointee holds a Master of Computer Applications (MCA) degree
- Stock has seen a 398.3% price return over the last 12 months despite missing financial data
Gujarat Inject Kerala Ltd has scheduled an Extra Ordinary General Meeting (EGM) for August 12, 2026, to seek shareholder approval for a major strategic pivot. The company intends to change its name to 'REGENOVA RENEWTECH LIMITED' to reflect a new focus on solar-related activities, moving away from its pharmaceutical roots. This follows a previous name change proposal from April 2025 which the board now seeks to rescind as it did not adequately reflect the new business direction. The stock has seen a significant 461.9% price return over the last 12 months, likely anticipating this diversification.
- EGM scheduled for August 12, 2026, to approve a pivot into solar-related activities
- Proposed name change to 'REGENOVA RENEWTECH LIMITED' from 'Gujarat Inject Kerala Limited'
- Rescinding a previous special resolution passed on April 3, 2025, for a different name change
- Cut-off date for e-voting eligibility set for August 5, 2026
- Remote e-voting period to run from August 8, 2026, to August 11, 2026
Gujarat Inject Kerala reported a massive 414.4% YoY revenue growth to 12.45 Cr in Q1 FY27, driven by its strategic pivot into the solar energy sector. Net profit surged to 1.25 Cr, which represents 69% of the total profit earned in the entire previous fiscal year (FY26). The company is formalizing this transition by proposing a name change to Regenova Renewtech Limited and has appointed Mr. Murli Shivshankaran Nair as Managing Director. While revenue declined sequentially from a peak Q4 FY26 of 30.70 Cr, the bottom-line remains significantly stronger than historical levels.
- Q1 FY27 Revenue grew 414.4% YoY to 12.45 Crore from 2.42 Crore.
- Net Profit (PAT) reached 1.25 Crore, a massive jump from 0.07 Crore in Q1 FY26.
- Q1 FY27 PAT accounts for 69% of the total FY26 full-year PAT of 1.81 Crore.
- Company operates its own 5MW solar project in Jakasana, Mehsana (Gujarat).
- Proposed name change to REGENOVA RENEWTECH LIMITED to reflect the shift from Pharma to Clean Tech.
Gujarat Inject Kerala Ltd has approved its unaudited financial results for the quarter ended June 30, 2026. The company reported a Basic EPS of Rs 1.24, representing a 44% increase from Rs 0.86 in the preceding quarter and a 10.7% increase from Rs 1.12 in the same quarter last year. Notably, the quarterly EPS of Rs 1.24 significantly exceeds the full-year FY26 EPS of Rs 0.05, suggesting a sharp recovery or high volatility in earnings. The statutory auditors, M/s. S Mandawat & Co., issued a limited review report with no material qualifications.
- Basic and Diluted EPS for Q1 FY27 stood at Rs 1.24.
- EPS grew 44.18% sequentially from Rs 0.86 in the March 2026 quarter.
- EPS grew 10.71% year-on-year from Rs 1.12 in the June 2025 quarter.
- The reported quarterly EPS of Rs 1.24 is substantially higher than the full-year FY26 EPS of Rs 0.05.
- Board meeting was efficient, concluding in 45 minutes (09:00 AM to 09:45 AM).
The Board of Gujarat Inject Kerala Ltd approved a name change to 'REGENOVA RENEWTECH LIMITED' on July 14, 2026, signaling a major strategic pivot. The company plans to shift its business focus from pharmaceuticals to solar-related activities. This proposal is subject to shareholder approval at the upcoming general meeting. While the stock has delivered a 461.9% return over the past 12 months, the financial details and execution plan for the solar venture remain undisclosed.
- Board approved name change to REGENOVA RENEWTECH LIMITED on July 14, 2026
- Company is pivoting from Pharmaceuticals to focus on solar-related activities
- Stock has seen a significant 12-month price return of 461.9%
- Board meeting concluded within 30 minutes (03:15 PM to 03:45 PM)
- The 6-month price return stands at 222.4% as of the announcement date
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
